Digital Health Investment Weekly Report Vol.167: Mosanna Therapeutics Raises $80M Series A, Atraverse Medical Secures $29.4M, and Guidehealth Closes $10M Strategic Round

Due to recent changes in the official account push mechanism, we welcome you to set Boom Health as a "starred" account on the homepage of the official account to get the latest trends and expert insights in the digital healthcare industry第一时间!

01 Global Digital Health Investment and Financing Overview

Metabolic Obstructive Sleep Apnea Treatment Company Mosanna Therapeutics Secures $80 Million in Series A Funding

On June 9, Mosanna Therapeutics, a treatment provider for metabolic obstructive sleep apnea, secured $80 million in Series A financing. The round was led by EQT Life Sciences and Pivotal bioVenture Partners, with participation from Forbion, Broadview Ventures, and Norwest. The proceeds will be used to advance Mosanna's nasal spray therapy, MOS118, through Phase II clinical trials while supporting the expansion of its product pipeline.

Left Heart Access Device Developer Atraverse Medical Secures $29.4 Million in Financing

On June 10, left heart access device developer Atraverse Medical secured $29.4 million in funding. This round of financing will be used to expand the commercial organization, enhance manufacturing operations, and launch other products in the R&D pipeline, accelerating the commercialization of its innovative HOTWIRE™ transseptal access technology.

AI Nursing Solutions Provider Guidehealth Secures $10 Million in Strategic Funding

On June 10, Guidehealth, a provider of artificial intelligence-powered care solutions, secured $10 million in strategic funding from Emory Healthcare. This round of financing will be used to accelerate Guidehealth's next phase of growth, drive the development of AI-powered care services, enhance patient care, advance disease prevention, and expand access to high-quality, value-based healthcare services.

Medical Device Manufacturer Dilon Technologies Secures $9 Million in Financing

On June 9, medical device manufacturer Dilon Technologies secured $9 million in financing from JGB Management Inc. This round of funding will support Dilon's continued double-digit revenue growth and operational expansion, driving its innovative product portfolio in the fields of biosurgery, breast cancer treatment, and diagnostics.

Hollow Microneedle Developer Zhonghui Pharmaceuticals Secures Nearly 50 Million Yuan in Seed and Angel Funding

On June 9, Zhonghui Pharmaceutical, a developer of hollow microneedles, secured nearly 50 million yuan in seed and angel funding from investors including Xincheng Investment, Aikang Innovation Forum, and Shaanxi Growth Fund. This round of financing will be used for the construction of pilot workshops, biobanks, production bases, and medical device certification applications, accelerating the commercialization and development of exosome products.

One-Stop Precision Medicine Service Platform Guidehealth Secures 40 Million Yuan in Series A Funding

On June 8, Guidehealth, a one-stop precision medicine service platform, secured 40 million yuan in its Series A round of financing, led by Zero Capital and Junwei Capital, with JiuHua HengChuang as a follow-up investor. The proceeds will be used for production line expansion, market development, research investment, and talent acquisition.

Amperos Health, a developer of AI billing platforms for healthcare, raises $4.2 million in seed funding

June 4, MedicalHealthcare AIAmperos Health, a billing platform developer, secures $4.2 million in seed funding from Uncork Capital, Neo, Nebular, OpenAI, Twilio, and Stripe. The funds will be used to accelerate the development of its AI-powered billing platform, enhancing the efficiency and accuracy of healthcare providers' billing processes.

Bexorg Collaborates with Biohaven to Advance AI-Driven CNS Drug Development

On June 11, Bexorg and Biohaven reached a research and development collaboration to advance the research and development of central nervous system (CNS) drugs using Bexorg's AI-driven Wholerain platform. Bexorg's platform restores metabolic and molecular activities in isolated human and pig brains by using custom-formulated artificial blood, enabling detailed analysis of transcriptomic, proteomic, and metabolic processes in brain tissue. The technology, initially developed at Yale University, helps build physiologically relevant datasets for AI-driven drug development.

Autobio Diagnostics and Maiksaid Reach Strategic Cooperation, Jointly Initiating a New Era of Urine Analysis

On June 9, Autobio Diagnostics and Maiksaid signed a strategic cooperation agreement in Suzhou to jointly promote the technological upgrade and intelligent transformation of urine analysis. The aim is to provide more efficient and accurate urine testing solutions, explore innovative applications of AI technology in this field, jointly expand the market, and support the intelligent transformation of clinical laboratories.

Health-E Commerce® Collaborates with LifeMD™ to Expand Telehealth Services, Offering Sleep Therapy Solutions

On June 9, Health-E Commerce® expanded its partnership with LifeMD™, a leader in the telemedicine field, to offer sleep therapy solutions to users through FSA Store® and HSA Store®. The collaboration aims to improve users' sleep quality by providing affordable and convenient FDA-approved prescription sleep therapy options. Through this partnership, Health-E Commerce® and LifeMD™ hope to provide more effective sleep health support to over 70 million Americans enrolled in tax-free health accounts while helping them save on costs.

Aseptic Pharmaceutical Compounding Service Provider ITH Group Limited Acquired by H.I.G. Capital

On June 9, investment firm H.I.G. Capital announced that its affiliate had acquired ITH Group Limited, a provider of sterile pharmaceutical compounding services. ITH Group focuses on delivering high-quality, patient-specific medications for chemotherapy, total parenteral nutrition, and central venous additive services, supporting the UK's National Health Service (NHS) and private healthcare sectors. This acquisition will enable ITH Group to continue its strong organic growth under H.I.G.'s support and drive the implementation of new initiatives, including expanding the company’s production capacity.

Mental Health Service Provider White Cloud Therapeutic Services Acquired by St. James RVA

On June 9, mental health service provider White Cloud Therapeutic Services (WCTS) was officially acquired by strategic healthcare buyer St. James RVA. Known for its client-centered, human-focused care model, WCTS offers individual, couples, and family therapy services. The acquisition, facilitated by Viking Mergers & Acquisitions, aims to help WCTS continue its growth while preserving the values and mission that have defined the practice since its inception.

Hollow Microneedle Developer Zhonghui Pharmaceuticals Acquires Lanwei Medicine

On June 9, Zhonghui Pharmaceutical, a developer of hollow microneedles, acquired Lanwei Medical, a medical aesthetics product developer. Zhonghui Pharmaceutical's core product, the hollow microneedle, is widely used in drug delivery, vaccine injection, and medical aesthetics injection fields. This acquisition represents an important strategic layout by Zhonghui Pharmaceutical in the medical aesthetics sector, aiming to further expand its industrial capabilities in the medical device and medical aesthetics innovation tracks.

Aging and Age-Related Disease Therapy Developer Juvenescence Acquires Ro5

On June 8, Juvenescence, a developer of therapies for aging and age-related diseases, acquired Ro5. Ro5 is a company focused on applying artificial intelligence and machine learning technologies to pharmaceutical research, aiming to streamline the drug discovery process. This acquisition aims to enhance Juvenescence's AI and machine learning capabilities in drug discovery and development by integrating Ro5's expertise, improve the efficiency of identifying potential therapeutic compounds, and further drive technological innovation in the pharmaceutical field.

Scientific Instrument Manufacturer Bruker Acquires Biocrates Life Sciences AG

On June 5, scientific instrument manufacturer Bruker Corporation acquired Biocrates Life Sciences AG, a biotechnology company. Biocrates is a developer of mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software, and services. Its technology platform integrates innovative sample preparation, metabolite identification, and data analysis, enabling standardized metabolomics to be accessible in laboratories worldwide. This acquisition will further strengthen Bruker's solutions in the fields of metabolomics and lipidomics and support its expansion into multi-omics solutions.

ArteryNet/Arterial Orange Industry Think Tank/Huaxing Capital/China Grand Health/Rock Health/Mobile Health News/Fierce Health, etc.

Compiled by: Hou Zhancái, Huáng Chāngjiàn‍‍‍

Share

Like

Click to view